StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note released on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Price Performance
Shares of PULM stock opened at $2.13 on Friday. The company’s fifty day moving average price is $2.07 and its two-hundred day moving average price is $2.03. The firm has a market capitalization of $7.77 million, a P/E ratio of -0.72 and a beta of 0.99. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $2.75.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%. The business had revenue of $1.55 million during the quarter.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- Stock Splits, Do They Really Impact Investors?
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- What is a Dividend King?
- Battle of the Retailers: Who Comes Out on Top?
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
